Additional Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    The University of Oklahoma Health Sciences Center
    Oklahoma City OK. 73104-5020
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Dr Anil Dhar Professional Medicine Corporation
    Windsor ON. N8X 5A6
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Northwestern Medicine - Northwestern Medicine Glen
    Glenview IL. 60026-8039
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    McGovern Medical School
    Houston TX. 77030-1501
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of California, San Francisco-Fresno
    Fresno CA. 93701
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Research Centers of America
    McKinney TX. 75071-7824
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Kelowna Allergy and Respiratory Health Clinic
    Kelowna BC. V1W 1V3
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of Kansas Medical Center
    Kansas City KS. 66160
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of Alabama at Birmingham
    Birmingham AL. 35294-3300
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Dynamic Drug Advancement Ltd.
    Ajax ON. L1S 2J5
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of California, San Francisco Medical Center
    San Francisco CA. 94115
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine
    Muncie IN. 47303-3432
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Central Florida Pulmonary Group, PA
    Orlando FL. 32803
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Southeastern Research Center
    Winston-Salem NC. 27103-4029
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Hannibal Regional Healthcare System HRMG Hannibal
    Hannibal MO. 63401-6890
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Pulmonix LLC
    Greensboro NC. 27403
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Coastal Pulmonary and Critical Care PLC
    Saint Petersburg FL. 33704-2733
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Renstar Medical Research
    Ocala FL. 34470
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    El Paso Pulmonary Association Elligo PPDS
    El Paso TX. 79902-1124
    View Details

  • Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

    Penn State Health Milton S. Hershey Medical Center
    Hershey PA. 17033
    View Details